Kindeva Drug Delivery

We hope you all had a festive holiday season and a very Happy New Year! 🎉 2024 was a year of incredible growth for us and the customers we serve. In 2025, we remain laser-focused on continuous innovation, unwavering quality and making a difference—one patient at a time. Learn more about how we can manufacture more tomorrows together: https://loom.ly/M9_gEoQ #CDMO #DrugManufacturing #DrugDelivery

As the year draws to a close, we're reflecting on what has been a landmark year for us. 2024 has been filled with expansion, technological advancements, and industry recognition. Here are a few of our highlights: 🌍 Expanded our global footprint: new facilities in Missouri and the UK, plus the acquisition of Summit Biosciences. 💚 Invested in cutting-edge technology: we received the first Optima isolated filling line to enhance our injectable fill-finish capabilities at our Bridgeton, MO, facility. 💪 Strengthened our commitment to global public health: donated ATNAA autoinjectors to aid civilians affected by the war in Ukraine. 🏆 Gained industry recognition: John Patton, Head of our Scientific Advisory Board, received the prestigious Charles G. Thiel Award. We're proud to be a leading CDMO, driving innovation and delivering value to our customers and patients worldwide, and we have our amazing team and incredible partnerships to thank. We are so excited to see what 2025 holds for us all, and most importantly the patients we impact. From all of us at Kindeva Drug Delivery, a very Happy New Year! #CDMO #DrugDelivery #Sustainability OPTIMA packaging group

Happy Holidays from Kindeva Drug Delivery! ✨ We're sending our warmest wishes to our incredible team, valued partners, and the patients we serve. We're grateful for your continued support and collaboration. Here's to a joyous holiday season filled with health, happiness, and festivities!

We are thrilled to announce that one of our Optima isolated filling lines has officially made its journey from Schwäbisch Hall, Germany, to its new home at our injectable hub in St. Louis, Missouri! 📍 This cutting-edge technology will enhance our production capacity, allowing us to manufacture over 100 million units annually across vials, cartridges, and syringes. The Factory Acceptance Testing (FAT) has already been successfully completed, ensuring that our new line meets the highest quality and performance standards. With qualification as the next step in the process, we are on track to revolutionize our aseptic fill-finish capabilities. We can’t wait to see the positive impact this partnership with OPTIMA packaging group will have on drug delivery and patient outcomes. Stay tuned for more updates as we continue this exciting journey! 👉 https://loom.ly/Th3DZ2c #KindevaXOptima #Injectables #DrugDelivery

It's time to unlock the potential of Microneedle Array Patches (MAPs)... MAPs are revolutionizing drug delivery, but navigating the journey from concept to commercialization can be complex. In our latest webinar, our experts address the key considerations for successful MAP development, including: 💡 Advantages of different MAP types 💡 Methods for patch characterization 💡 Techniques to evaluate performance 💡 Benefits of optimized product evaluation Download the webinar to learn how to accelerate your MAP development and minimize risks: https://loom.ly/muPwFAQ #MicroneedleArrayPatches #DrugDelivery #DrugDelivery #CDMO #Pharma

A new era in aseptic fill-finish is quite literally arriving! Our state-of-the-art Optima isolated filling line is making its way from Schwäbisch Hall, Germany, to our injectable hub in St. Louis, Missouri! 📍📦 This cutting-edge technology will boost production, enhance flexibility and elevate quality. Stay tuned as we revolutionize our aseptic fill-finish capabilities! Learn more here: https://loom.ly/Th3DZ2c #KindevaXOptima #Injectables #DrugDelivery OPTIMA packaging group

Day two of the Drug Delivery to the Lungs Conference (DDL)) Conference is almost over! It's been a pleasure meeting so many of you already. We've thoroughly enjoyed discussing how we can support the development and manufacture of innovative inhalation therapies that improve patient outcomes. DDL is the perfect place to learn more about our expertise in: 👉 Pressurized Metered-Dose Inhalers (pMDIs) 👉 Dry Powder Inhalers (DPIs) 👉 Nasal sprays Are you ready to bring your therapy to the world? Visit us at booth #430 or schedule a meeting here: https://loom.ly/KEWljzc [loom.ly] 👥 Our attendees: David Stevens, Andy Burns, Stewart Griffiths, Barzin Gavtash, Ben Myatt, Neha Patel, Phil Cocks, Jim Lister, Nicholas Smalley, Andre Lavin, Sarah Gadd, Olivia Brittain, Harry Dahya, Jonathan Walder, Steven Powell, Jennifer Riter, Hossain CHIZARI, Jody Hawkes, Ruixin Zhou and Carolyn Jordan, Ph.D. #LungHealth #RespiratoryHealth #CDMO

HFA152a is a promising #greenpropellant option with the potential to reduce the environmental impact of #pMDIs without compromising patient care. In this white paper published with Fierce Pharma, we share considerations for a smoother transition. Download your copy today: https://lnkd.in/g-vJneBn

From low-GWP propellant characteristics to nasal #drugdelivery, Kindeva’s team will share their expertise on a broad range of topics at the Drug Delivery to the Lungs (DDL) conference. Stop by our poster presentations for your inside look at our latest developments and insights. https://lnkd.in/gqffqrdz #DDL2024 #CombineForces Drug Delivery to the Lungs Conference (DDL)

Kindeva is a leading inhalation drug delivery #CDMO, with a full range of capabilities and unrivaled know-how. Watch this video featuring our Vice President, MDI Business Development, Andy Burns, to dive deeper into the benefits of combining forces with us. https://lnkd.in/d_uk7ZJq #Drugdelivery #Inhalation